First Patient Implanted in PIERRE IDE Clinical Study of the ThecaFlex DRx System for Administration of Spinraza
LOWELL, Mass., Jan. 3, 2024. Alycone Therapeutics Inc. (Alcyone), a biotechnology company pioneering next-generation precision genetic therapies and precision delivery solutions of therapies for complex neurological conditions, announced the first... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 3, 2024 Category: Pharmaceuticals Source Type: clinical trials
Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers
Conditions: Diabetic Foot Ulcers Interventions: Drug: Antimicrobial Peptide PL-5 Topical Spray and Placebo Sponsors: Jiangsu ProteLight Pharmaceutical& Biotechnology Co., Ltd.; Parexel Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 3, 2024 Category: Research Source Type: clinical trials
Performance of PEAR 2.0 Software in Prescribing Biotherapy in Patients With Rheumatoid Arthritis
Conditions: Polyarthritis; Rheumatoid Interventions: Other: Patients with planned biotherapy Sponsors: CEN Biotech; MYEXPRESION Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 1, 2024 Category: Research Source Type: clinical trials
IND Application Submitted to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
CAMBRIDGE, Mass., Dec. 28, 2023. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has submitted an Investigational New Drug (IND) application to the U.S.... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 28, 2023 Category: Pharmaceuticals Source Type: clinical trials
A Study of EXG102-031 in Participants With wAMD
Conditions: Neovascular Age-related Macular Degeneration Interventions: Biological: EXG102-031 Sponsors: Hangzhou Jiayin Biotech Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 28, 2023 Category: Research Source Type: clinical trials
Effects of Probiotics on Metabolic Syndrome ,Intestinal Microflora and SCFA.
Conditions: Metabolic Syndrome Interventions: Dietary Supplement: Probiotics 1; Dietary Supplement: Probiotics 2; Dietary Supplement: Probiotics 3; Dietary Supplement: Probiotics 4; Dietary Supplement: Probiotics 5; Dietary Supplement: Placebo 1; Dietary Supplement: Probiotics 6; Dietary Supplement: Probiotics 7; Dietary Supplement: Placebo 2 Sponsors: Glac Biotech Co., Ltd Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 28, 2023 Category: Research Source Type: clinical trials
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
Conditions: Pancreatic Ductal Carcinoma Interventions: Drug: ProAgio Dose Levels (DL) 1,2,3,4; Drug: Gemcitabine, nab paclitaxel Sponsors: ProDa BioTech, LLC; University of Alabama at Birmingham; Georgia State University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 25, 2023 Category: Research Source Type: clinical trials
a Phase I Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
Conditions: B Cell Lymphoma; Non Hodgkin Lymphoma Interventions: Biological: MC-1-50 Sponsors: Chongqing Precision Biotech Co., Ltd; Peking University Cancer Hospital& Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 22, 2023 Category: Research Source Type: clinical trials
CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Conditions: Relapsed B-cell Acute Lymphoblastic Leukemia; Refractory B-cell Acute Lymphoblastic Leukemia Interventions: Biological: CAR-T-19 cell injection Sponsors: Beijing Yongtai Ruike Biotechnology Company Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 22, 2023 Category: Research Source Type: clinical trials
Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
Conditions: B Cell Lymphoma; Non Hodgkin Lymphoma Interventions: Biological: MC-1-50 Sponsors: Chongqing Precision Biotech Co., Ltd; Peking University Cancer Hospital& Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 22, 2023 Category: Research Source Type: clinical trials
FDA approves initiation of Phase II clinical trial of MTX652 in Acute Kidney Injury
CAMBRIDGE, England, Dec. 14, 2023. Mission Therapeutics ( " Mission " or the " Company " ), a clinical-stage biotech developing first-in-class therapeutics targeting mitophagy, today announces that the US Food and Drug Administration (FDA) has approved... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 15, 2023 Category: Pharmaceuticals Source Type: clinical trials
MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors
Conditions: Advanced Solid Tumor Interventions: Drug: TCR-MAGE-A4 T-Cells Sponsors: Peking University; Shanghai Ming Ju Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 14, 2023 Category: Research Source Type: clinical trials
Acesion Pharma announces Nature Medicine publication of clinical results in Atrial Fibrillation
COPENHAGEN, Denmark, Dec. 13, 2023. Acesion Pharma ( " Acesion " or " the Company " ), a biotech company pioneering first-in-class novel therapies for atrial fibrillation ( " AF " ), the most common cardiac arrhythmia, today announces the publication of data... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 14, 2023 Category: Pharmaceuticals Source Type: clinical trials
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers
Conditions: Advanced Solid Tumor Interventions: Drug: ND-003 tablets; Drug: ND-003 tablets; Drug: ND-003 tablets; Drug: ND-003 tablets; Drug: ND-003 tablets; Drug: ND-003 tablets; Drug: ND-003 tablets; Drug: ND-003 tablets Sponsors: Shenzhen NewDEL Biotech, Co., Ltd; Shenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 13, 2023 Category: Research Source Type: clinical trials
A Phase 1 Trial of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vaccination
Conditions: SARS-CoV-2; COVID-19 Vaccine Interventions: Biological: 30 μg dose of LYB002V14; Biological: 60μg dose of LYB002V14; Biological: placebo Sponsors: Guangzhou Patronus Biotech Co., Ltd.; Yantai Patronus Biotech Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 13, 2023 Category: Research Source Type: clinical trials
